董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Koby | 男 | Director | 48 | 20.16万美元 | 未持股 | 2021-09-02 |
| Patrick Beyer | 男 | Director | 55 | 20.88万美元 | 未持股 | 2021-09-02 |
| Paul LaViolette | 男 | Director | 63 | 20.16万美元 | 未持股 | 2021-09-02 |
| Thomas M. Patton | 男 | Director | 57 | 20.91万美元 | 未持股 | 2021-09-02 |
| Stavros Vizirgianakis | 男 | Chief Executive Officer and Director | 50 | 275.62万美元 | 未持股 | 2021-09-02 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joseph P. Dwyer | 男 | Chief Financial Officer, Treasurer and Secretary | 65 | 110.32万美元 | 未持股 | 2021-09-02 |
| Sharon W. Klugewicz | 女 | Chief Operating Officer | 53 | 37.20万美元 | 未持股 | 2021-09-02 |
| Jay Waggoner | 男 | Senior Vice President of Sales - Wound | 55 | 未披露 | 未持股 | 2021-09-02 |
| Stavros Vizirgianakis | 男 | Chief Executive Officer and Director | 50 | 275.62万美元 | 未持股 | 2021-09-02 |
| Robert S. Ludecker | 男 | Senior Vice President of Global Sales and Marketing | 53 | 66.77万美元 | 未持股 | 2021-09-02 |
董事简历
中英对照 | 中文 | 英文- Michael Koby
-
Michael Koby于2014年共同创立1315Capital，目前担任其创始合伙人。在成立1315Capital之前，Koby先生曾担任Palm Ventures（一家专注于私募股权的家族办公室）的董事总经理，从2010年到2014年，Koby先生领导了该公司所有的梦百合投资。在此之前，1997年至1999年和2004年至2010年，Koby先生是Galen Partners（一家梦百合成长型股权投资公司）的投资者。Koby先生还在1999年至2002年期间担任Novoste Corporation和美敦力公司的业务开发职务，并在1995年至1997年期间担任Dillon，Read&Co.的梦百合投资银行分析师。Koby先生拥有沃顿商学院（Wharton School）的梦百合管理工商管理硕士学位和康奈尔大学（Cornell University）的工商管理硕士学位。
Michael Koby Capital in 2014 and currently serves as its Founding Partner. Prior to founding 1315 Capital, Mr. Koby was a Managing Director of Palm Ventures, a private-equity focused family office, where Mr. Koby led all healthcare investing from 2010 to 2014. Prior to that, Mr. Koby was an investor at Galen Partners, a healthcare growth equity investment firm, from 1997 to 1999 and from 2004 to 2010. Mr. Koby also served in business development roles with Novoste Corporation and Medtronic, Inc. between 1999 and 2002 and as a healthcare investment banking analyst at Dillon, Read & Co. from 1995 to 1997. Mr. Koby holds an MBA in Healthcare Management from The Wharton School and a B.S. from Cornell University. - Michael Koby于2014年共同创立1315Capital，目前担任其创始合伙人。在成立1315Capital之前，Koby先生曾担任Palm Ventures（一家专注于私募股权的家族办公室）的董事总经理，从2010年到2014年，Koby先生领导了该公司所有的梦百合投资。在此之前，1997年至1999年和2004年至2010年，Koby先生是Galen Partners（一家梦百合成长型股权投资公司）的投资者。Koby先生还在1999年至2002年期间担任Novoste Corporation和美敦力公司的业务开发职务，并在1995年至1997年期间担任Dillon，Read&Co.的梦百合投资银行分析师。Koby先生拥有沃顿商学院（Wharton School）的梦百合管理工商管理硕士学位和康奈尔大学（Cornell University）的工商管理硕士学位。
- Michael Koby Capital in 2014 and currently serves as its Founding Partner. Prior to founding 1315 Capital, Mr. Koby was a Managing Director of Palm Ventures, a private-equity focused family office, where Mr. Koby led all healthcare investing from 2010 to 2014. Prior to that, Mr. Koby was an investor at Galen Partners, a healthcare growth equity investment firm, from 1997 to 1999 and from 2004 to 2010. Mr. Koby also served in business development roles with Novoste Corporation and Medtronic, Inc. between 1999 and 2002 and as a healthcare investment banking analyst at Dillon, Read & Co. from 1995 to 1997. Mr. Koby holds an MBA in Healthcare Management from The Wharton School and a B.S. from Cornell University.
- Patrick Beyer
-
Patrick Beyer是Conmed Corporation“；ConMed”；（一家上市医疗技术公司）的国际和全球骨科总裁，自2020年10月起担任该职位。2014年12月至2020年10月，Beyer先生曾担任ConMed International的总裁。在加入ConMed之前，2010年至2014年，Beyer先生担任ICNET的首席执行官，这是一家私人持有的传染病控制软件公司，该公司被出售。此前，他曾任职史赛克公司21年，在那里他曾领导Stryker Europe（从2005年到2009年）、Stryker UK（从2002年到2005年）、Stryker UK（南非和爱尔兰）和Stryker Medical（从1999年到2002年）。Beyer先生毕业于卡拉马祖学院（Kalamazoo College），获得西密歇根大学（Western Michigan University）经济学学士学位，获得金融MBA学位和哈佛商学院（Harvard Business School）高级管理课程。
Patrick Beyer is the President of International and Global Orthopedics for ConMed Corporation “ConMed”, a publicly held medical technology company, a position in which he has served since October 2020. Mr. Beyer previously served as President of ConMed International from December 2014 to October 2020. Prior to joining ConMed, Mr. Beyer served as Chief Executive Officer of ICNet, a privately held infectious control software company from 2010 to 2014 when the company was sold. Prior to this, Mr. Beyer spent 21 years at Stryker Corporation where he led Stryker Europe from 2005 to 2009; Stryker UK, South Africa and Ireland from 2002 to 2005 and Stryker Medical from 1999 to 2002. Mr. Beyer graduated from Kalamazoo College with a BA in Economics, Western Michigan University with an MBA in Finance and Harvard Business School’s Advanced Management Program. - Patrick Beyer是Conmed Corporation“；ConMed”；（一家上市医疗技术公司）的国际和全球骨科总裁，自2020年10月起担任该职位。2014年12月至2020年10月，Beyer先生曾担任ConMed International的总裁。在加入ConMed之前，2010年至2014年，Beyer先生担任ICNET的首席执行官，这是一家私人持有的传染病控制软件公司，该公司被出售。此前，他曾任职史赛克公司21年，在那里他曾领导Stryker Europe（从2005年到2009年）、Stryker UK（从2002年到2005年）、Stryker UK（南非和爱尔兰）和Stryker Medical（从1999年到2002年）。Beyer先生毕业于卡拉马祖学院（Kalamazoo College），获得西密歇根大学（Western Michigan University）经济学学士学位，获得金融MBA学位和哈佛商学院（Harvard Business School）高级管理课程。
- Patrick Beyer is the President of International and Global Orthopedics for ConMed Corporation “ConMed”, a publicly held medical technology company, a position in which he has served since October 2020. Mr. Beyer previously served as President of ConMed International from December 2014 to October 2020. Prior to joining ConMed, Mr. Beyer served as Chief Executive Officer of ICNet, a privately held infectious control software company from 2010 to 2014 when the company was sold. Prior to this, Mr. Beyer spent 21 years at Stryker Corporation where he led Stryker Europe from 2005 to 2009; Stryker UK, South Africa and Ireland from 2002 to 2005 and Stryker Medical from 1999 to 2002. Mr. Beyer graduated from Kalamazoo College with a BA in Economics, Western Michigan University with an MBA in Finance and Harvard Business School’s Advanced Management Program.
- Paul LaViolette
-
Paul LaViolette，自2008年8月起，他担任董事会成员；2011年1月至2012年5月，担任首席董事；自2012年5月起，担任董事会主席。2011年1月，他成为SV生命科学的合伙人，目前担任SV生命科学的管理合伙人兼首席营运官。他拥有超过33年的全球性医疗技术市场推广及管理经验。他最近担任波士顿科学公司（或BSC）的首席运营官，一家医疗设备超过80亿收支的领导者。在BSC的15年里，他担任首席营运官、集团总裁、Cardiology总裁和国际总裁，公司的利润以超过20倍增长速度增长。他综合20家收购，并导致广泛的产品开发、运营和世界各地的商业机构。此前，他曾担任CR Bard的营销和一般管理职位，并在Kendall Covidien公司担任各种营销职务。他目前担任CardioFocus、CardioKinetix、Coridea NC2 CSA医疗，直流设备、直接流医疗、Thoratec、TransEnterix、ValenTx和医疗设备制造商协会的董事。他目前担任CardioFocus、直流设备、TransEnterix和直接流量的董事会主席。他目前还担任Thoratec的薪酬委员会的主席和CardioKinetix和直流设备的薪酬委员会成员。他获得了费尔菲尔德大学心理学学士学位和波士顿学院工商管理硕士学位。
Paul LaViolette joined SV Health Investors, a leading life sciences growth equity and venture capital firm, in 2009 and has served as Managing Partner since 2014. Mr. LaViolette currently serves as Chairman of the Board of, Asensus Surgical, Inc., a publicly held surgical robotics company, and serves as a member of the board of directors of Edwards Lifesciences Corp., a publicly held medical technology company, and continues to serve on the board of directors of several other early and growth stage private medical device companies. Additionally, Mr. LaViolette has served as a director of the Medical Device Manufacturers Association for the past decade and as Chairman of the Innovation Advisory Board for the Mass General Brigham Health System for the past five years. Prior to joining SV Health Investors, Mr. LaViolette spent nearly three decades building and leading medical device businesses. From 1994 to 2008 Mr. LaViolette served in several roles at Boston Scientific Corporation including President of Cardiology and International, Group President of Cardiovascular and Endosurgery, and Chief Operating Officer. Prior to joining Boston Scientific Corporation, Mr. LaViolette served in general management and commercial leadership roles at C.R. Bard from 1984 to 1993 and at Kendall Medtronic from 1980 to 1984. Mr. LaViolette holds an MBA from Boston College and a B.A. in Psychology from Fairfield University. - Paul LaViolette，自2008年8月起，他担任董事会成员；2011年1月至2012年5月，担任首席董事；自2012年5月起，担任董事会主席。2011年1月，他成为SV生命科学的合伙人，目前担任SV生命科学的管理合伙人兼首席营运官。他拥有超过33年的全球性医疗技术市场推广及管理经验。他最近担任波士顿科学公司（或BSC）的首席运营官，一家医疗设备超过80亿收支的领导者。在BSC的15年里，他担任首席营运官、集团总裁、Cardiology总裁和国际总裁，公司的利润以超过20倍增长速度增长。他综合20家收购，并导致广泛的产品开发、运营和世界各地的商业机构。此前，他曾担任CR Bard的营销和一般管理职位，并在Kendall Covidien公司担任各种营销职务。他目前担任CardioFocus、CardioKinetix、Coridea NC2 CSA医疗，直流设备、直接流医疗、Thoratec、TransEnterix、ValenTx和医疗设备制造商协会的董事。他目前担任CardioFocus、直流设备、TransEnterix和直接流量的董事会主席。他目前还担任Thoratec的薪酬委员会的主席和CardioKinetix和直流设备的薪酬委员会成员。他获得了费尔菲尔德大学心理学学士学位和波士顿学院工商管理硕士学位。
- Paul LaViolette joined SV Health Investors, a leading life sciences growth equity and venture capital firm, in 2009 and has served as Managing Partner since 2014. Mr. LaViolette currently serves as Chairman of the Board of, Asensus Surgical, Inc., a publicly held surgical robotics company, and serves as a member of the board of directors of Edwards Lifesciences Corp., a publicly held medical technology company, and continues to serve on the board of directors of several other early and growth stage private medical device companies. Additionally, Mr. LaViolette has served as a director of the Medical Device Manufacturers Association for the past decade and as Chairman of the Innovation Advisory Board for the Mass General Brigham Health System for the past five years. Prior to joining SV Health Investors, Mr. LaViolette spent nearly three decades building and leading medical device businesses. From 1994 to 2008 Mr. LaViolette served in several roles at Boston Scientific Corporation including President of Cardiology and International, Group President of Cardiovascular and Endosurgery, and Chief Operating Officer. Prior to joining Boston Scientific Corporation, Mr. LaViolette served in general management and commercial leadership roles at C.R. Bard from 1984 to 1993 and at Kendall Medtronic from 1980 to 1984. Mr. LaViolette holds an MBA from Boston College and a B.A. in Psychology from Fairfield University.
- Thomas M. Patton
-
Thomas M. Patton自2010年8月起一直担任CASMED的总裁，首席执行官和董事会成员。他曾担任Wright Medical Group（一家位于田纳西州，孟菲斯的骨科器械公司）的CEO，以及Novametrix Medical Systems（一家位于康涅狄格州，沃灵福德病人监护公司）的总裁。2003年到2010年期间，Patton先生曾担任Ferrer Freeman & Company的医疗保健私人募股的顾问，并在2006年到2007年期间担任Informed Medical Communications的临时CEO。Patton先生曾是QDx, Inc.（一家在2003年起步的开发血液诊断平台的公司）的联合创始人和CEO。Patton先生曾上过The College of the Holy Cross，并在该学校主修经济学和会计学。在他以优异的成绩从Georgetown University 法律中心毕业后，Patton先生曾在华盛顿特区的Williams & Connolly律师事务所工作。之后，他作为总顾问加入了Wright Medical Group，并在他上任CEO之前，担任了各种行政职务。
Thomas M. Patton,is a seasoned healthcare executive and board member with operational, strategic, financial, legal, compliance and transactional experience, from start-ups to growth companies, both public and private. He currently is an advisor to the private equity firm SV Health Investors, is the executive chairman of the board of directors of Spineology, Inc., a privately held, therapeutic devices corporation, and serves on the board of the Connecticut Port Authority. He also serves on the private company boards' of directors of each of Packing Compliance Labs, Robling Medical, LLC and Miach Orthopedics, Inc. He was the chief executive officer and member of the board of directors of Ximedica, LLC, a private medical products outsource design and development company from August 2020 to May 2021. From 2015 to 2021, he also served on the board of Misonix, Inc., a publicly traded ultrasonic surgical tools and wound care company, and chaired that company's audit committee, from October 2015 to November 2021 and served as president and chief executive officer of CAS Medical Systems, a publicly traded developer and distributor of patient monitoring equipment, from 2010-2019. His prior experience includes roles as co-founder, president and chief executive officer of QDx, Inc., a developer of unique micro-fluidic diagnostic technology utilizing digital imaging techniques for hematologic analysis, as president and chief operating officer of Novametrix Medical Systems, Inc., and as chief executive officer of Wright Medical Technology, Inc. Mr. Patton has served on more than a dozen boards of directors for both public and private medical products and services companies. Mr. Patton holds a B.A. in economics from Holy Cross University and J.D. from Georgetown University Law Center. - Thomas M. Patton自2010年8月起一直担任CASMED的总裁，首席执行官和董事会成员。他曾担任Wright Medical Group（一家位于田纳西州，孟菲斯的骨科器械公司）的CEO，以及Novametrix Medical Systems（一家位于康涅狄格州，沃灵福德病人监护公司）的总裁。2003年到2010年期间，Patton先生曾担任Ferrer Freeman & Company的医疗保健私人募股的顾问，并在2006年到2007年期间担任Informed Medical Communications的临时CEO。Patton先生曾是QDx, Inc.（一家在2003年起步的开发血液诊断平台的公司）的联合创始人和CEO。Patton先生曾上过The College of the Holy Cross，并在该学校主修经济学和会计学。在他以优异的成绩从Georgetown University 法律中心毕业后，Patton先生曾在华盛顿特区的Williams & Connolly律师事务所工作。之后，他作为总顾问加入了Wright Medical Group，并在他上任CEO之前，担任了各种行政职务。
- Thomas M. Patton,is a seasoned healthcare executive and board member with operational, strategic, financial, legal, compliance and transactional experience, from start-ups to growth companies, both public and private. He currently is an advisor to the private equity firm SV Health Investors, is the executive chairman of the board of directors of Spineology, Inc., a privately held, therapeutic devices corporation, and serves on the board of the Connecticut Port Authority. He also serves on the private company boards' of directors of each of Packing Compliance Labs, Robling Medical, LLC and Miach Orthopedics, Inc. He was the chief executive officer and member of the board of directors of Ximedica, LLC, a private medical products outsource design and development company from August 2020 to May 2021. From 2015 to 2021, he also served on the board of Misonix, Inc., a publicly traded ultrasonic surgical tools and wound care company, and chaired that company's audit committee, from October 2015 to November 2021 and served as president and chief executive officer of CAS Medical Systems, a publicly traded developer and distributor of patient monitoring equipment, from 2010-2019. His prior experience includes roles as co-founder, president and chief executive officer of QDx, Inc., a developer of unique micro-fluidic diagnostic technology utilizing digital imaging techniques for hematologic analysis, as president and chief operating officer of Novametrix Medical Systems, Inc., and as chief executive officer of Wright Medical Technology, Inc. Mr. Patton has served on more than a dozen boards of directors for both public and private medical products and services companies. Mr. Patton holds a B.A. in economics from Holy Cross University and J.D. from Georgetown University Law Center.
- Stavros Vizirgianakis
-
Stavros Vizirgianakis，自2022年8月起担任董事会成员。Vizirgianakis先生于2022年8月因Xtant Medical Holdings， Inc.的私募而当选为董事会成员。Vizirgianakis先生是Misonix， Inc.（医疗设备公司，Bioventus Inc.于2021年收购）的前首席执行官。Vizirgianakis先生在医疗设备领域拥有杰出的职业生涯，曾担任United States Surgical Corporation撒哈拉以南非洲地区的销售总监，后来担任Tyco Healthcare南非总经理。2006年，Vizirgianakis先生共同创立了Surgical Innovations，该公司已成为非洲地区最大的私营医疗设备分销商之一，现在是约翰内斯堡证券交易所上市实体Ascendis Health的一部分。Vizirgianakis先生从2014年1月到2016年7月担任Ascendis Medical的总经理。Vizirgianakis先生从2016年9月到2021年10月担任Misonix的总裁兼首席执行官。Vizirgianakis先生目前担任Apyx Medical Corporation （NASDAQ： Apyx）（一家先进的能源技术公司）的董事会主席，以及Medinotec， Inc. （OTCQX： MDNC）（一家医疗设备公司）的董事会成员。他曾担任Bioventus Inc.和Tenaxis Medical， Inc.的董事会成员，是该领域众多医疗设备初创公司和成熟公司的战略投资者和顾问。Vizirgianakis先生拥有South Africa大学的商业学位。
Stavros Vizirgianakis,has served as a member of Board since August 2022. Mr. Vizirgianakis was elected to the Board in connection with Xtant Medical Holdings, Inc. private placement in August 2022. Mr. Vizirgianakis is the former Chief Executive Officer of Misonix, Inc., a medical device company that Bioventus Inc. acquired in 2021. Mr. Vizirgianakis has a distinguished career in the medical devices field having worked for United States Surgical Corporation as director of sales for sub-Saharan Africa and later Tyco Healthcare in the capacity of General Manager South Africa. In 2006, Mr. Vizirgianakis co-founded Surgical Innovations, which has become one of the largest privately owned medical device distributors in the African region, and now part of the Johannesburg Stock Exchange listed entity Ascendis Health. Mr. Vizirgianakis was Managing Director of Ascendis Medical from January 2014 through July 2016. Mr. Vizirgianakis served as the President and Chief Executive Officer of Misonix from September 2016 through October 2021. Mr. Vizirgianakis currently serves as Chair of the board of directors of Apyx Medical Corporation (NASDAQ: APYX), an advanced energy technology company, and as a member of the board of directors of Medinotec, Inc. (OTCQX: MDNC), a medical device company. He previously served on the board of directors of Bioventus Inc. and Tenaxis Medical, Inc. and is a strategic investor and advisor to numerous medical device startups and established companies in this field. Mr. Vizirgianakis has a Degree in Commerce from the University of South Africa. - Stavros Vizirgianakis，自2022年8月起担任董事会成员。Vizirgianakis先生于2022年8月因Xtant Medical Holdings， Inc.的私募而当选为董事会成员。Vizirgianakis先生是Misonix， Inc.（医疗设备公司，Bioventus Inc.于2021年收购）的前首席执行官。Vizirgianakis先生在医疗设备领域拥有杰出的职业生涯，曾担任United States Surgical Corporation撒哈拉以南非洲地区的销售总监，后来担任Tyco Healthcare南非总经理。2006年，Vizirgianakis先生共同创立了Surgical Innovations，该公司已成为非洲地区最大的私营医疗设备分销商之一，现在是约翰内斯堡证券交易所上市实体Ascendis Health的一部分。Vizirgianakis先生从2014年1月到2016年7月担任Ascendis Medical的总经理。Vizirgianakis先生从2016年9月到2021年10月担任Misonix的总裁兼首席执行官。Vizirgianakis先生目前担任Apyx Medical Corporation （NASDAQ： Apyx）（一家先进的能源技术公司）的董事会主席，以及Medinotec， Inc. （OTCQX： MDNC）（一家医疗设备公司）的董事会成员。他曾担任Bioventus Inc.和Tenaxis Medical， Inc.的董事会成员，是该领域众多医疗设备初创公司和成熟公司的战略投资者和顾问。Vizirgianakis先生拥有South Africa大学的商业学位。
- Stavros Vizirgianakis,has served as a member of Board since August 2022. Mr. Vizirgianakis was elected to the Board in connection with Xtant Medical Holdings, Inc. private placement in August 2022. Mr. Vizirgianakis is the former Chief Executive Officer of Misonix, Inc., a medical device company that Bioventus Inc. acquired in 2021. Mr. Vizirgianakis has a distinguished career in the medical devices field having worked for United States Surgical Corporation as director of sales for sub-Saharan Africa and later Tyco Healthcare in the capacity of General Manager South Africa. In 2006, Mr. Vizirgianakis co-founded Surgical Innovations, which has become one of the largest privately owned medical device distributors in the African region, and now part of the Johannesburg Stock Exchange listed entity Ascendis Health. Mr. Vizirgianakis was Managing Director of Ascendis Medical from January 2014 through July 2016. Mr. Vizirgianakis served as the President and Chief Executive Officer of Misonix from September 2016 through October 2021. Mr. Vizirgianakis currently serves as Chair of the board of directors of Apyx Medical Corporation (NASDAQ: APYX), an advanced energy technology company, and as a member of the board of directors of Medinotec, Inc. (OTCQX: MDNC), a medical device company. He previously served on the board of directors of Bioventus Inc. and Tenaxis Medical, Inc. and is a strategic investor and advisor to numerous medical device startups and established companies in this field. Mr. Vizirgianakis has a Degree in Commerce from the University of South Africa.
高管简历
中英对照 | 中文 | 英文- Joseph P. Dwyer
Joseph P. Dwyer，他曾担任公司的临时首席财务官（2016年9月以来）。2015年6月至今，他曾为多个公司提供财务咨询和咨询服务。此前，他曾担任Virtual Piggy, Inc.（上市科技公司）的首席财务官（2012年11月至2015年6月）。加入Virtual Piggy公司之前，他曾担任OpenLink Financial, Inc.（私人公司，提供能源、大宗商品和资本市场的交易和风险管理的软件解决方案）的首席财务官。2011年至2012年，他曾担任Energy Solutions International, Inc.（一家民营公司，为能源公司和管道运营商提供管道管理软件）的董事会成员兼审计委员会的主席，也曾担任临时首席行政官。2010年至2011年，他曾担任Capstone Advisory Group, LLC（私人控股的金融咨询公司，提供企业重组、诉讼支持、法务会计、专家证词和估值服务）的首席行政官。他曾担任Verint Systems, Inc（一家软件公司，在纳斯达克的全球市场上市）的顾问（2009年至2010年），协助SEC报告和合规。2005年至2009年，他曾担任AXS-One Inc.（上市软件公司）的首席财务官兼执行副总裁。2004年间，他曾担任Synergen, Inc.（私有软件公司，提供公用事业能源技术）的首席财务官。2004年之前，他曾担任Caminus Corporation（一个企业应用程序软件公司，以前是在纳斯达克国家市场上市）的首席财务官兼执行副总裁、ACTV, Inc.（数字媒体公司，以前是在纳斯达克国家市场上市）的首席财务官、Winstar Global Products, Inc（头发护理、洗澡和美容产品的制造商和经销商，于1995年被Winstar Communications收购）的首席财务官。他于1995年担任Winstar Communications的高级财务副总裁。他于1978年获得the University of Notre Dame的会计工商管理学士学位。他是纽约注册会计师。
Joseph P. Dwyer has served as our Chief Financial Officer since August 2017 and as our Treasurer and Secretary since September 2017 and previously served as Interim Chief Financial Officer from September 2016 to August 2017. From June 2015 to the present, Mr. Dwyer has provided financial consulting and advisory services to various companies, through the firms Dwyer Holdings and TechCXO. Prior thereto, from November 2012 until June 2015 he was Chief Financial Officer of Virtual Piggy, Inc., a publicly-traded technology company. Prior to joining Virtual Piggy, Mr. Dwyer served as Chief Financial Officer of OpenLink Financial, Inc., a privately held company, which provides software solutions for trading and risk management in the energy, commodity, and capital markets. During 2011 and 2012 Mr. Dwyer was a member of the board of directors and chairman of the audit committee and served as interim Chief Administrative Officer of Energy Solutions International, Inc., a privately-held company providing pipeline management software to energy companies and pipeline operators. From 2010 through 2011 Mr. Dwyer served as Chief Administrative Officer of Capstone Advisory Group, LLC, a privately-held financial advisory firm providing corporate restructuring, litigation support, forensic accounting, expert testimony and valuation services. Mr. Dwyer served as a consultant to Verint Systems, Inc., a software company listed on the NASDAQ Global Market, from 2009 through 2010 assisting with SEC reporting and compliance. From 2005 through 2009 Mr. Dwyer served as Chief Financial Officer and Executive Vice President of AXS-One Inc., a publicly traded software company. During 2004 Mr. Dwyer served as Chief Financial Officer of Synergen, Inc., a privately held software company providing energy technology to utilities. Prior to 2004 Mr. Dwyer also served as Chief Financial Officer and Executive Vice President of Caminus Corporation, an enterprise application software company that was formerly listed on the NASDAQ National Market, chief financial officer of ACTV, Inc., a digital media company that was formerly listed on the NASDAQ National Market, and Chief Financial Officer of Winstar Global Products, Inc., a manufacturer and distributor of hair care, bath and beauty products until its acquisition by Winstar Communications, Inc. in 1995 when Mr. Dwyer went on to serve as Senior Vice President, Finance of Winstar Communications. Mr. Dwyer received his BBA in Accounting from the University of Notre Dame in 1978 and is licensed as a Certified Public Accountant in the State of New York.- Joseph P. Dwyer，他曾担任公司的临时首席财务官（2016年9月以来）。2015年6月至今，他曾为多个公司提供财务咨询和咨询服务。此前，他曾担任Virtual Piggy, Inc.（上市科技公司）的首席财务官（2012年11月至2015年6月）。加入Virtual Piggy公司之前，他曾担任OpenLink Financial, Inc.（私人公司，提供能源、大宗商品和资本市场的交易和风险管理的软件解决方案）的首席财务官。2011年至2012年，他曾担任Energy Solutions International, Inc.（一家民营公司，为能源公司和管道运营商提供管道管理软件）的董事会成员兼审计委员会的主席，也曾担任临时首席行政官。2010年至2011年，他曾担任Capstone Advisory Group, LLC（私人控股的金融咨询公司，提供企业重组、诉讼支持、法务会计、专家证词和估值服务）的首席行政官。他曾担任Verint Systems, Inc（一家软件公司，在纳斯达克的全球市场上市）的顾问（2009年至2010年），协助SEC报告和合规。2005年至2009年，他曾担任AXS-One Inc.（上市软件公司）的首席财务官兼执行副总裁。2004年间，他曾担任Synergen, Inc.（私有软件公司，提供公用事业能源技术）的首席财务官。2004年之前，他曾担任Caminus Corporation（一个企业应用程序软件公司，以前是在纳斯达克国家市场上市）的首席财务官兼执行副总裁、ACTV, Inc.（数字媒体公司，以前是在纳斯达克国家市场上市）的首席财务官、Winstar Global Products, Inc（头发护理、洗澡和美容产品的制造商和经销商，于1995年被Winstar Communications收购）的首席财务官。他于1995年担任Winstar Communications的高级财务副总裁。他于1978年获得the University of Notre Dame的会计工商管理学士学位。他是纽约注册会计师。
- Joseph P. Dwyer has served as our Chief Financial Officer since August 2017 and as our Treasurer and Secretary since September 2017 and previously served as Interim Chief Financial Officer from September 2016 to August 2017. From June 2015 to the present, Mr. Dwyer has provided financial consulting and advisory services to various companies, through the firms Dwyer Holdings and TechCXO. Prior thereto, from November 2012 until June 2015 he was Chief Financial Officer of Virtual Piggy, Inc., a publicly-traded technology company. Prior to joining Virtual Piggy, Mr. Dwyer served as Chief Financial Officer of OpenLink Financial, Inc., a privately held company, which provides software solutions for trading and risk management in the energy, commodity, and capital markets. During 2011 and 2012 Mr. Dwyer was a member of the board of directors and chairman of the audit committee and served as interim Chief Administrative Officer of Energy Solutions International, Inc., a privately-held company providing pipeline management software to energy companies and pipeline operators. From 2010 through 2011 Mr. Dwyer served as Chief Administrative Officer of Capstone Advisory Group, LLC, a privately-held financial advisory firm providing corporate restructuring, litigation support, forensic accounting, expert testimony and valuation services. Mr. Dwyer served as a consultant to Verint Systems, Inc., a software company listed on the NASDAQ Global Market, from 2009 through 2010 assisting with SEC reporting and compliance. From 2005 through 2009 Mr. Dwyer served as Chief Financial Officer and Executive Vice President of AXS-One Inc., a publicly traded software company. During 2004 Mr. Dwyer served as Chief Financial Officer of Synergen, Inc., a privately held software company providing energy technology to utilities. Prior to 2004 Mr. Dwyer also served as Chief Financial Officer and Executive Vice President of Caminus Corporation, an enterprise application software company that was formerly listed on the NASDAQ National Market, chief financial officer of ACTV, Inc., a digital media company that was formerly listed on the NASDAQ National Market, and Chief Financial Officer of Winstar Global Products, Inc., a manufacturer and distributor of hair care, bath and beauty products until its acquisition by Winstar Communications, Inc. in 1995 when Mr. Dwyer went on to serve as Senior Vice President, Finance of Winstar Communications. Mr. Dwyer received his BBA in Accounting from the University of Notre Dame in 1978 and is licensed as a Certified Public Accountant in the State of New York.
- Sharon W. Klugewicz
Sharon W.Klugewicz于2019年3月成为首席运营官。在加入公司之前，Klugewicz女士于2018年7月至2019年2月担任传染病诊断测试制造商Chembio Diagnostic Systems，Inc.的首席质量与法规事务官。在担任首席质量和监管事务官之前，克鲁格维奇曾在Chembio担任多个职位，包括2016年9月至2018年6月担任美洲地区总裁，2017年5月至2017年10月担任代理首席执行官，2013年5月至2016年8月担任首席运营官，2016年8月担任Vice President，QA/QC/技术操作，直到2013年4月。在2012年9月加入Chembio之前，Klugewicz女士曾在过滤，分离和净化技术的世界领导者颇尔公司担任过多个执行职位，包括SR。高级科学与实验室服务部副总裁Pall Life Sciences分部全球质量运营副总裁，以及营销产品管理和现场技术服务副总裁。Klugewicz女士拥有Adelphi University的生物化学硕士学位和Stony Brook University的神经生物学学士学位。
Sharon W. Klugewicz became Chief Operating Officer in March 2019. Prior to joining the Company, Ms. Klugewicz served from July 2018 to February 2019 as Chief Quality & Regulatory Affairs Officer for Chembio Diagnostic Systems, Inc. “Chembio”, a manufacturer of diagnostic tests for infectious diseases. Prior to her role as Chief Quality & Regulatory Affairs Officer, Ms. Klugewicz served in various roles for Chembio, including President, Americas Region from September 2016 to June 2018 acting CEO from May 2017 to October 2017 Chief Operating Officer from May 2013 to August 2016 and Vice President, QA/QC/Technical Operations until April 2013. Prior to joining Chembio in September 2012 Ms. Klugewicz, held a number of executive positions at Pall Corporation, a world leader in filtration, separation and purification technologies, over her 21-year tenure there, including Sr. VP, Scientific & Laboratory Services, Sr. VP, Global Quality Operations in the Pall Life Sciences Division, as well as in Marketing Product Management, and Field Technical Services. Ms. Klugewicz holds an M.S. in Biochemistry from Adelphi University and a B.S. in Neurobiology from Stony Brook University.- Sharon W.Klugewicz于2019年3月成为首席运营官。在加入公司之前，Klugewicz女士于2018年7月至2019年2月担任传染病诊断测试制造商Chembio Diagnostic Systems，Inc.的首席质量与法规事务官。在担任首席质量和监管事务官之前，克鲁格维奇曾在Chembio担任多个职位，包括2016年9月至2018年6月担任美洲地区总裁，2017年5月至2017年10月担任代理首席执行官，2013年5月至2016年8月担任首席运营官，2016年8月担任Vice President，QA/QC/技术操作，直到2013年4月。在2012年9月加入Chembio之前，Klugewicz女士曾在过滤，分离和净化技术的世界领导者颇尔公司担任过多个执行职位，包括SR。高级科学与实验室服务部副总裁Pall Life Sciences分部全球质量运营副总裁，以及营销产品管理和现场技术服务副总裁。Klugewicz女士拥有Adelphi University的生物化学硕士学位和Stony Brook University的神经生物学学士学位。
- Sharon W. Klugewicz became Chief Operating Officer in March 2019. Prior to joining the Company, Ms. Klugewicz served from July 2018 to February 2019 as Chief Quality & Regulatory Affairs Officer for Chembio Diagnostic Systems, Inc. “Chembio”, a manufacturer of diagnostic tests for infectious diseases. Prior to her role as Chief Quality & Regulatory Affairs Officer, Ms. Klugewicz served in various roles for Chembio, including President, Americas Region from September 2016 to June 2018 acting CEO from May 2017 to October 2017 Chief Operating Officer from May 2013 to August 2016 and Vice President, QA/QC/Technical Operations until April 2013. Prior to joining Chembio in September 2012 Ms. Klugewicz, held a number of executive positions at Pall Corporation, a world leader in filtration, separation and purification technologies, over her 21-year tenure there, including Sr. VP, Scientific & Laboratory Services, Sr. VP, Global Quality Operations in the Pall Life Sciences Division, as well as in Marketing Product Management, and Field Technical Services. Ms. Klugewicz holds an M.S. in Biochemistry from Adelphi University and a B.S. in Neurobiology from Stony Brook University.
- Jay Waggoner
Jay Waggoner于2020年11月成为Wound全球销售执行副总裁。在2019年9月加入Misonix担任销售高级副总裁之前，Waggoner先生从2015年6月到2019年9月我们收购Solsys时担任Solsys Medical LLC的销售副总裁。加入Solsys之前，2009年12月至2015年6月，Waggoner先生在Ethicon担任多个高级销售职位，这是一家医疗设备公司，是强生公司家族的一部分。从1992年3月到2015年6月，Waggoner先生还在Ethicon，DePuy Spine和Medtronic担任多个高级职位，这三家公司都是医疗设备公司。Waggoner先生拥有科罗拉多大学博尔德分校的学士学位。
Jay Waggoner became Executive Vice President of Global Sales, Wound in November 2020. Prior to joining Misonix as Senior Vice President of Sales in September 2019 Mr. Waggoner served as Vice President of Sales for Solsys Medical LLC from June 2015 to September 2019 when we acquired Solsys. Prior to Solsys, Mr. Waggoner served from December 2009 to June 2015 in a variety of senior sales positions at Ethicon, a medical device company that is part of the Johnson & Johnson family of companies. Mr. Waggoner has also served in various senior roles from March 1992 to June 2015 in Ethicon, Depuy Spine and Medtronic, each a medical device company. Mr. Waggoner holds a B.S. degree from the University of Colorado at Boulder.- Jay Waggoner于2020年11月成为Wound全球销售执行副总裁。在2019年9月加入Misonix担任销售高级副总裁之前，Waggoner先生从2015年6月到2019年9月我们收购Solsys时担任Solsys Medical LLC的销售副总裁。加入Solsys之前，2009年12月至2015年6月，Waggoner先生在Ethicon担任多个高级销售职位，这是一家医疗设备公司，是强生公司家族的一部分。从1992年3月到2015年6月，Waggoner先生还在Ethicon，DePuy Spine和Medtronic担任多个高级职位，这三家公司都是医疗设备公司。Waggoner先生拥有科罗拉多大学博尔德分校的学士学位。
- Jay Waggoner became Executive Vice President of Global Sales, Wound in November 2020. Prior to joining Misonix as Senior Vice President of Sales in September 2019 Mr. Waggoner served as Vice President of Sales for Solsys Medical LLC from June 2015 to September 2019 when we acquired Solsys. Prior to Solsys, Mr. Waggoner served from December 2009 to June 2015 in a variety of senior sales positions at Ethicon, a medical device company that is part of the Johnson & Johnson family of companies. Mr. Waggoner has also served in various senior roles from March 1992 to June 2015 in Ethicon, Depuy Spine and Medtronic, each a medical device company. Mr. Waggoner holds a B.S. degree from the University of Colorado at Boulder.
- Stavros Vizirgianakis
Stavros Vizirgianakis，自2022年8月起担任董事会成员。Vizirgianakis先生于2022年8月因Xtant Medical Holdings， Inc.的私募而当选为董事会成员。Vizirgianakis先生是Misonix， Inc.（医疗设备公司，Bioventus Inc.于2021年收购）的前首席执行官。Vizirgianakis先生在医疗设备领域拥有杰出的职业生涯，曾担任United States Surgical Corporation撒哈拉以南非洲地区的销售总监，后来担任Tyco Healthcare南非总经理。2006年，Vizirgianakis先生共同创立了Surgical Innovations，该公司已成为非洲地区最大的私营医疗设备分销商之一，现在是约翰内斯堡证券交易所上市实体Ascendis Health的一部分。Vizirgianakis先生从2014年1月到2016年7月担任Ascendis Medical的总经理。Vizirgianakis先生从2016年9月到2021年10月担任Misonix的总裁兼首席执行官。Vizirgianakis先生目前担任Apyx Medical Corporation （NASDAQ： Apyx）（一家先进的能源技术公司）的董事会主席，以及Medinotec， Inc. （OTCQX： MDNC）（一家医疗设备公司）的董事会成员。他曾担任Bioventus Inc.和Tenaxis Medical， Inc.的董事会成员，是该领域众多医疗设备初创公司和成熟公司的战略投资者和顾问。Vizirgianakis先生拥有South Africa大学的商业学位。
Stavros Vizirgianakis,has served as a member of Board since August 2022. Mr. Vizirgianakis was elected to the Board in connection with Xtant Medical Holdings, Inc. private placement in August 2022. Mr. Vizirgianakis is the former Chief Executive Officer of Misonix, Inc., a medical device company that Bioventus Inc. acquired in 2021. Mr. Vizirgianakis has a distinguished career in the medical devices field having worked for United States Surgical Corporation as director of sales for sub-Saharan Africa and later Tyco Healthcare in the capacity of General Manager South Africa. In 2006, Mr. Vizirgianakis co-founded Surgical Innovations, which has become one of the largest privately owned medical device distributors in the African region, and now part of the Johannesburg Stock Exchange listed entity Ascendis Health. Mr. Vizirgianakis was Managing Director of Ascendis Medical from January 2014 through July 2016. Mr. Vizirgianakis served as the President and Chief Executive Officer of Misonix from September 2016 through October 2021. Mr. Vizirgianakis currently serves as Chair of the board of directors of Apyx Medical Corporation (NASDAQ: APYX), an advanced energy technology company, and as a member of the board of directors of Medinotec, Inc. (OTCQX: MDNC), a medical device company. He previously served on the board of directors of Bioventus Inc. and Tenaxis Medical, Inc. and is a strategic investor and advisor to numerous medical device startups and established companies in this field. Mr. Vizirgianakis has a Degree in Commerce from the University of South Africa.- Stavros Vizirgianakis，自2022年8月起担任董事会成员。Vizirgianakis先生于2022年8月因Xtant Medical Holdings， Inc.的私募而当选为董事会成员。Vizirgianakis先生是Misonix， Inc.（医疗设备公司，Bioventus Inc.于2021年收购）的前首席执行官。Vizirgianakis先生在医疗设备领域拥有杰出的职业生涯，曾担任United States Surgical Corporation撒哈拉以南非洲地区的销售总监，后来担任Tyco Healthcare南非总经理。2006年，Vizirgianakis先生共同创立了Surgical Innovations，该公司已成为非洲地区最大的私营医疗设备分销商之一，现在是约翰内斯堡证券交易所上市实体Ascendis Health的一部分。Vizirgianakis先生从2014年1月到2016年7月担任Ascendis Medical的总经理。Vizirgianakis先生从2016年9月到2021年10月担任Misonix的总裁兼首席执行官。Vizirgianakis先生目前担任Apyx Medical Corporation （NASDAQ： Apyx）（一家先进的能源技术公司）的董事会主席，以及Medinotec， Inc. （OTCQX： MDNC）（一家医疗设备公司）的董事会成员。他曾担任Bioventus Inc.和Tenaxis Medical， Inc.的董事会成员，是该领域众多医疗设备初创公司和成熟公司的战略投资者和顾问。Vizirgianakis先生拥有South Africa大学的商业学位。
- Stavros Vizirgianakis,has served as a member of Board since August 2022. Mr. Vizirgianakis was elected to the Board in connection with Xtant Medical Holdings, Inc. private placement in August 2022. Mr. Vizirgianakis is the former Chief Executive Officer of Misonix, Inc., a medical device company that Bioventus Inc. acquired in 2021. Mr. Vizirgianakis has a distinguished career in the medical devices field having worked for United States Surgical Corporation as director of sales for sub-Saharan Africa and later Tyco Healthcare in the capacity of General Manager South Africa. In 2006, Mr. Vizirgianakis co-founded Surgical Innovations, which has become one of the largest privately owned medical device distributors in the African region, and now part of the Johannesburg Stock Exchange listed entity Ascendis Health. Mr. Vizirgianakis was Managing Director of Ascendis Medical from January 2014 through July 2016. Mr. Vizirgianakis served as the President and Chief Executive Officer of Misonix from September 2016 through October 2021. Mr. Vizirgianakis currently serves as Chair of the board of directors of Apyx Medical Corporation (NASDAQ: APYX), an advanced energy technology company, and as a member of the board of directors of Medinotec, Inc. (OTCQX: MDNC), a medical device company. He previously served on the board of directors of Bioventus Inc. and Tenaxis Medical, Inc. and is a strategic investor and advisor to numerous medical device startups and established companies in this field. Mr. Vizirgianakis has a Degree in Commerce from the University of South Africa.
- Robert S. Ludecker
Robert S. Ludecker， 于2013年5月成为全球销售和营销副总裁。在加入该公司以前，他曾于2011年2月-2013年5月期间，在一家纳斯达克（NASDAQ）上市的从事促进骨骼损伤和疾病治疗产品（包括整形外科、脊柱产品、运动医学领域）发展和商业化的生物技术公司--BioMimetic Therapeutics担任全球销售和营销副总裁。在BioMimetic之前， 2008年2月-2011年2月期间，他曾在Small Bone Innovations股份有限公司（一家从事小骨头的整容公司（私营））和Smith & Nephew PLC（一家总部在英国（UK）的、植入物重建和广泛的医疗器械组合的全球供应商）担任各种销售和营销职位。他拥有Kenyon大学的学士学位。
Robert S. Ludecker became Senior Vice President of Global Sales and Marketing in May 2015. Prior to joining the Company as Global Vice President of Sales and Marketing in May 2013 Mr. Ludecker served from February 2011 to May 2013 as Vice President of Global Sales and Marketing for BioMimetic Therapeutics, a NASDAQ-listed biotechnology company, specializing in the development and commercialization of products which promote the healing of musculoskeletal injury and diseases, including orthopedic, spine, and sports medicine applications. Prior to BioMimetic, Mr. Ludecker served from February 2008 to February 2011 in a variety of senior sales and marketing leadership positions with Small Bone Innovations, a private New York City-based orthopedic company specializing in small bones, and Smith and Nephew, a leading U.K.-based global provider of orthopedic reconstruction implants and a broad portfolio of medical instruments and supplies. Mr. Ludecker holds a B.A. degree from Kenyon College.- Robert S. Ludecker， 于2013年5月成为全球销售和营销副总裁。在加入该公司以前，他曾于2011年2月-2013年5月期间，在一家纳斯达克（NASDAQ）上市的从事促进骨骼损伤和疾病治疗产品（包括整形外科、脊柱产品、运动医学领域）发展和商业化的生物技术公司--BioMimetic Therapeutics担任全球销售和营销副总裁。在BioMimetic之前， 2008年2月-2011年2月期间，他曾在Small Bone Innovations股份有限公司（一家从事小骨头的整容公司（私营））和Smith & Nephew PLC（一家总部在英国（UK）的、植入物重建和广泛的医疗器械组合的全球供应商）担任各种销售和营销职位。他拥有Kenyon大学的学士学位。
- Robert S. Ludecker became Senior Vice President of Global Sales and Marketing in May 2015. Prior to joining the Company as Global Vice President of Sales and Marketing in May 2013 Mr. Ludecker served from February 2011 to May 2013 as Vice President of Global Sales and Marketing for BioMimetic Therapeutics, a NASDAQ-listed biotechnology company, specializing in the development and commercialization of products which promote the healing of musculoskeletal injury and diseases, including orthopedic, spine, and sports medicine applications. Prior to BioMimetic, Mr. Ludecker served from February 2008 to February 2011 in a variety of senior sales and marketing leadership positions with Small Bone Innovations, a private New York City-based orthopedic company specializing in small bones, and Smith and Nephew, a leading U.K.-based global provider of orthopedic reconstruction implants and a broad portfolio of medical instruments and supplies. Mr. Ludecker holds a B.A. degree from Kenyon College.